Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women

Journal of Clinical Oncology

Volumn 28, Issue 7, 2010, Pages 1161-1167

  Dunbier, Anita K ^a   Anderson, Helen ^a   Ghazoui, Zara ^a   Folkerd, Elizabeth J ^a   A'Hern, Roger ^a   Crowder, Robert J ^a   Hoog, Jeremy ^a   Smith, Ian E ^a   Osin, Peter ^a   Nerurkar, Ashutosh ^a   Parker, Joel S ^a   Perou, Charles M ^a   Ellis, Matthew J ^a   Dowsett, Mitch ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; LETROZOLE; PDZ PROTEIN; PROGESTERONE RECEPTOR; PROTEIN GREB1; PROTEIN PDZK1; RNA; TREFOIL FACTOR 1; TREFOIL PEPTIDE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; NITRILE; TRIAZOLE DERIVATIVE;

ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CONTROLLED STUDY; DISEASE MARKER; ESTRADIOL BLOOD LEVEL; ESTROGEN RESPONSIVE ELEMENT; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; TRANSCRIPTION INITIATION; TREATMENT OUTCOME; TUMOR BIOPSY; AGED; BLOOD; BREAST TUMOR; CHEMISTRY; METABOLISM; MIDDLE AGED;

AGED; BREAST NEOPLASMS; ESTRADIOL; ESTROGENS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NITRILES; POSTMENOPAUSE; RECEPTORS, ESTROGEN; TRIAZOLES;

EID: 77949908545     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.9616     Document Type: Article

References (36)

1. Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001 (Pubitemid 32878711)
2. Miller WR, Larionov A, Renshaw L, et al: Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J Clin Oncol 27:1382-1387, 2009
3. Horwitz KB, Koseki Y, McGuire WL: Estrogen control of progesterone receptor in human breast cancer: Role of estradiol and antiestrogen. Endocrinology 103:1742-1751, 1978 (Pubitemid 9051866)
4. Miller WR, Dixon JM, Macfarlane L, et al: Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur J Cancer 39:462-468, 2003 (Pubitemid 36173690)
5. Ellis MJ, Coop A, Singh B, et al: Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 63:6523-6531, 2003 (Pubitemid 37255206)
6. Dowsett M, Ebbs SR, Dixon JM, et al: Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer - A study from the IMPACT trialists. J Clin Oncol 23:2477-2492, 2005 (Pubitemid 47050838)
7. Anderson H, Bulun S, Smith I, et al: Predictors of response to aromatase inhibitors. J Steroid Biochem Mol Biol 106:49-54, 2007 (Pubitemid 47362644)
8. Elledge RM, Green S, Pugh R, et al: Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study. Int J Cancer 89:111-117, 2000 (Pubitemid 30185917)
9. Brown AM, Jeltsch JM, Roberts M, et al: Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc Natl Acad Sci U S A 81:6344-6348, 1984 (Pubitemid 15220836)
10. Frasor J, Stossi F, Danes JM, et al: Selective estrogen receptor modulators: Discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 64:1522-1533, 2004 (Pubitemid 38235626)
11. Key T, Appleby P, Barnes I, et al: Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies. J Natl Cancer Inst 94:606-616, 2002 (Pubitemid 34498648)
12. Chlebowski RT, Hendrix SL, Langer RD, et al: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative randomized trial. JAMA 289:3243-3253, 2003 (Pubitemid 37430077)
13. Simpson ER, Dowsett M: Aromatase and its inhibitors: Significance for breast cancer therapy. Recent Prog Horm Res 57:317-338, 2002
14. Smith IE, Walsh G, Skene A, et al: A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 25:3816-3822, 2007 (Pubitemid 47477255)
15. Olson JA Jr, Budd GT, Carey LA, et al: Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: Results from a multicenter phase II trial. J Am Coll Surg 208:906-914, 2009; discussion 915-916
16. Du P, Kibbe WA, Lin SM: Lumi: A pipeline for processing Illumina microarray. Bioinformatics 24: 1547-1548, 2008 (Pubitemid 351911712)
17. Crowder RJ, Phommaly C, Tao Y, et al: PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 69: 3955-3962, 2009
18. Korn EL, Troendle JF, McShane LM, et al: Controlling the number of false discoveries: Application to high-dimensional genomic data. J Stat Plan Interfer 124:379-398, 2004 (Pubitemid 38830084)
19. Subramanian A, Tamayo P, Mootha VK, et al: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression pro-files. Proc Natl Acad Sci U S A 102:15545-15550, 2005 (Pubitemid 41528093)
20. Parker JS, Mullins M, Cheang MC, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167, 2009
21. Dowsett M, Goss PE, Powles TJ, et al: Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: Optimization of therapeutic dose and route. Cancer Res 47:1957-1961, 1987
22. Mackay A, Urruticoechea A, Dixon JM, et al: Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res 9:R37, 2007
23. Miller WR, Larionov AA, Renshaw L, et al: Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet Genomics 17:813-826, 2007 (Pubitemid 47462295)
24. Rae JM, Johnson MD, Scheys JO, et al: GREB 1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res Treat 92:141-149, 2005 (Pubitemid 40933578)
25. Tanaka N, Yonekura H, Yamagishi S, et al: The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 275: 25781-25790, 2000
26. Molloy CA, May FE, Westley BR: Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. J Biol Chem 275:12565-12571, 2000 (Pubitemid 30241403)
27. Campbell-Thompson ML: Estrogen receptor alpha and beta expression in upper gastrointestinal tract with regulation of trefoil factor family 2 mRNA levels in ovariectomized rats. Biochem Biophys Res Commun 240:478-483, 1997
28. Stossi F, Barnett DH, Frasor J, et al: Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human osteosarcoma cells: Distinct and common target genes for these receptors. Endocrinology 145:3473-3486, 2004 (Pubitemid 38830020)
29. Shang Y, Hu X, DiRenzo J, et al: Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103:843-852, 2000
30. Dowsett M, Smith IE, Ebbs SR, et al: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99:167-170, 2007
31. Dowsett M, Folkerd E: Deficits in plasma oestradiol measurement in studies and management of breast cancer. Breast Cancer Res 7:1-4, 2005 (Pubitemid 40214529)
32. Yue W, Santner SJ, Masamura S, et al: Determinants of tissue estradiol levels and biologic responsiveness in breast tumors. Breast Cancer Res Treat 49:S1-S7, 1998 (suppl 1); discussion S33-S37
33. Sikora MJ, Cordero KE, Larios JM, et al: The androgen metabolite 5alpha-androstane-3beta, 17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: Implications for aromatase inhibitor resistance. Breast Cancer Res Treat 115:289-296, 2009
34. Dorgan JF, Stanczyk FZ, Longcope C, et al: Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5-androstene-3 beta, 17 beta-diol to risk of breast cancer in postmenopausal women Cancer Epidemiol Biomarkers Prev 6:177-181, 1997
35. Lønning PE, Helle SI, Johannessen DC, et al: Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. Breast Cancer Res Treat 39:335-341, 1996 (Pubitemid 26278949)
36. Dunning AM, Dowsett M, Healey CS, et al: Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 96:936-945, 2004 (Pubitemid 38868140)